ATR and non-small cell lung carcinoma: Pharmacological inhibitors of key DDR regulators, including PARP, ATM/Ataxia telangiectasia and Rad3-related protein (ATR), and CHK1/2, have demonstrated the potential to impair DNA repair processes, disrupt radio-resistance mechanisms, and sensitize NSCLC cells to radiation therapy [6,16,28].